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Neuroendocrine control of satiation
Abstract: Eating is a simple behavior with complex func-
tions. The unconscious neuroendocrine process that stops 
eating and brings a meal to its end is called satiation. 
Energy homeostasis is mediated accomplished through 
the control of meal size via satiation. It involves neural 
integrations of phasic negative-feedback signals related 
to ingested food and tonic signals, such as those related 
to adipose tissue mass. Energy homeostasis is accom-
plished through adjustments in meal size brought about 
by changes in these satiation signals. The best understood 
meal-derived satiation signals arise from gastrointestinal 
nutrient sensing. Gastrointestinal hormones secreted dur-
ing the meal, including cholecystokinin, glucagon-like 
peptide 1, and PYY, mediate most of these. Other physi-
ological signals arise from activation of metabolic-sensing 
neurons, mainly in the hypothalamus and caudal brain-
stem. We review both classes of satiation signal and their 
integration in the brain, including their processing by 
melanocortin, neuropeptide Y/agouti-related peptide, ser-
otonin, noradrenaline, and oxytocin neurons. Our review 
is not comprehensive; rather, we discuss only what we 
consider the best-understood mechanisms of satiation, 
with a special focus on normally operating physiological 
mechanisms.
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Introduction
Energy homeostasis refers to two processes: (a) the regu-
lation of an adequate readily available supply of energy 
metabolites in the circulation and (b) the regulation of 
adipose tissue mass, which is the major energy store. These 
are among the most important biological functions of any 
organism. Both aspects of energy homeostasis are linked 
to eating. Eating normally results in the entry of sufficient 
energy metabolites from the intestines into the circula-
tion except during intense exercise and the “postabsorp-
tive state”, i.e., early in the morning, when the stomach is 
entirely empty and intestinal absorption slows. Glycogen-
olysis and lipolysis take up the slack in such situations. 
Over the longer term, stability of the adipose tissue mass, 
or “lipostasis”, requires that the energetic content of food 
eaten be balanced with energy expended in metabolism 
and physical work (in adults, in whom growth can be 
ignored). If this energy equation is imbalanced, fat stores 
and body weight will drift upward or downward. Perhaps 
the most convincing evidence that adipose tissue mass 
is actively regulated is that experimental perturbations 
of adipose tissue mass lead to compensatory eating and 
energy expenditure responses that re-establish normality 
[1]. Figure 1 shows an example [2, 3].
Humans, rats, and mice eat in the form of meals. 
Thus, study of the neuroendocrine bases of eating should, 
and ultimately must, target the mechanisms controlling 
meal size and frequency. Furthermore, the homeostatic 
controls of eating described above must be manifested as 
changes in patterns of meal frequency or meal size. Meal 
size is the clearly decisive parameter in rats: (a) the total 
amount eaten over days correlates with average meal size 
but not with meal frequency [4]; (b) diluting the energy 
content of the diet results in immediate increases in meal 
size, with little change in meal frequency [5]; (c) in a cold 
environment, rats ate larger, but less frequent, meals [6]; 
(d) diabetic rats that cannot metabolize glucose normally 
increase meal size rather than meal frequency [5, 7, 8]; 
(e) during lactation, rats increase meal size sooner and 
more than meal frequency [9]; (f) the increased energetic 
demand brought about by female rats’ avid wheel running 
is met by increasing meal size [10]; (g) the hyperphagia 
of obese Zucker rats, which have defective leptin receptor 
signaling, is caused by increased meal size rather than 
meal frequency [11, 12], and chronic leptin administra-
tion increases meal size, not meal frequency [13, 14], and 
perhaps most convincing, (h) compensatory eating in rats 
recovering from enforced overweight or forced under-
weight is usually accomplished by adjusting meal size, 
not meal frequency [2, 3, 15–17] (Table 1). In contrast to the 
selective effect of energy-homeostatic challenges on meal 
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Table 1 Food intake and meal patterns during postinsulin hypophagia.
 
 
Baseline level 
 
Postinsulin hypophagia
Diurnal  Nocturnal Diurnal  Nocturnal
Food intake, g/12 h  7.2 ± 0.5  18.5 ± 0.4  5.6 ± 0.5a  12.8 ± 0.5a
No. of meals   4.3 ± 0.3  8.6 ± 0.4  3.7 ± 0.2  7.5 ± 0.5
Meal duration, min   13.5 ± 0.8  17.2 ± 1.0  10.2 ± 0.8b  13.0 ± 1.0a
Values are mean ± SE for 11 rats. Baselines are the rats’ mean values 
during 4 days before insulin treatment. Hypophagic values were meas-
ured on the second day after the end of insulin treatment. aHypophagic 
value different from baseline, paired t-test, 2α < 0.05. bp < 0.01.
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Figure 1 Changes in food intake (top) and body weight (bottom) 
during and after insulin injections. Filled circles, injected animals; 
open circles, control animals; shaded bar, injection period.  
*Different from controls.
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Figure 2 Diagram of proposed meal size controls.
as the direct controls of meal size, consists of negative 
feedback that are generated during meals in the gastro-
intestinal tract from preabsorptive nutrient stimuli, and 
their primary effect is to inhibit eating and bring the meal 
to an end, i.e., to produce satiation. This feedback mecha-
nism is shown schematically in the inner feedback loop 
in Figure 2. We will discuss the gastrointestinal nutrient-
sensing mechanisms mediating the direct controls of 
satiation below. The second class of feedback comprises 
circulating energy metabolites and hormones involved in 
energy metabolism. These arise from nutrient absorption 
and from organs involved in energy metabolism such as 
the liver, pancreas, and adipose tissue, and they act on a 
widely distributed set of what Levin and colleagues [23, 24] 
call “metabolic-sensing neurons”. Lipostasis is one of the 
important functions of this feedback which is shown sche-
matically in the outer feedback loop in Figure 2. Finally, 
we will discuss the central neural networks that integrate 
this information and produce satiation. An important 
point reflected in Figure 2 is that current understanding 
indicates that the gastrointestinal nutrient- and meta-
bolic-sensing neural networks converge in the caudal 
brainstem, which also organizes the motor control of sati-
ation. Note that this current understanding indicates that 
this indirect feedback loop controls meal size by converg-
ing on the central neural networks mediating the direct 
control of satiation.
Figure 2 also shows several other controls of meal 
size that we do not include in this review. For example, 
size, rats’ meal frequency seems more sensitive to the very 
different homeostatic challenges such as those occurring 
during illness [18–21]. Furthermore, in humans, social con-
ditioning is normally the major controller of meal timing. 
For these reasons, we focus here on the mechanisms by 
which energy homeostasis controls meal size.
Current understanding indicates that the contribu-
tions of meal size to the two aspects of energy homeo-
stasis described above arise from two different classes of 
feedback signals. The first class, described by Smith [22] 
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although “hunger” mechanisms such as ghrelin con-
tribute primarily to meal initiation, they also affect 
meal size [25]. Their contribution to homeostatic eating, 
however, is less clear. “Hedonics” refers to the pleasur-
able aspects of orosensory food stimuli. Food hedonics 
can tonically increase meal size and lead to increased 
adiposity [26–28]. In the modern Western “obesogenic” 
environment [27, 28], these effects more often detract 
from homeostasis than contribute to it. The same is true 
of several stressors that primarily affect meal size [25, 
29, 30].
Our review is not comprehensive; rather, we review 
only what we consider are presently the best-understood 
mechanisms of satiation. Finally, we also emphasize that 
most, probably all, of the physiological controls of meal 
size that we review are powerfully modulated, first, by 
sex and, second, by experience. We do not review these 
topics; the interested reader is referred to [31] and [32–36], 
respectively.
Gastrointestinal nutrient sensing 
and satiation
Which gastrointestinal nutrient-sensing 
mechanisms contribute to satiation?
In this section, we review the molecular gastrointestinal 
nutrient-sensing mechanisms and gastrointestinal hor-
mone-signaling mechanisms involved in satiation. Gas-
trointestinal nutrient sensors contribute to the control 
of eating through three mechanisms. First, they initi-
ate neural signaling via vagal and spinal visceral affer-
ent nerves. The vagus in particular is a major route of 
information between the gut and the brain. Vagal affer-
ents project to the nucleus of the solitary tract (NTS) 
and, via the NTS, throughout the dorsal vagal complex 
(DVC) of the hindbrain, an important node in the central 
neural network controlling eating. Second, gastrointes-
tinal nutrient sensors stimulate enteroendocrine cells 
in the gastrointestinal mucosa to release a variety of 
hormones with roles in digestion, metabolism, and the 
control of eating. Our review concentrates on three hor-
mones with putative roles in satiation: cholecystokinin 
(CCK; secreted by I-cells), glucagon-like peptide 1 (GLP-1; 
secreted by L-cells), and peptide YY (PYY; secreted by 
L-cells). 
The apical surfaces of the enteroendocrine cells 
contact the gut lumen, whereas the basolateral surface 
contacts the lamina propria, in close proximity to the cir-
culatory and lymphatic systems. Because of this “open-
type” morphology, these cells are in perfect position to 
sense incoming nutrients as they arrive in the gut lumen, 
perform intracellular integratory operations, and generate 
a response in the form of hormone secretion. As in other 
endocrine cell types, alterations in membrane potential 
are coupled via voltage-gated Ca2+ entry to the release of 
secretory vesicles. All enteroendocrine cell types studied 
to date are also responsive to signals that activate G-pro-
tein-coupled receptors (GPCRs). Finally, gastrointestinal 
nutrient sensors affect the enteric nervous system. Enteric 
nervous system reflexes, often involving gastrointestinal 
hormones, regulate gastrointestinal nutrient flow during 
and after eating by mixing, propelling, and separating 
luminal contents. The regulation of gastric emptying is 
an especially important function that indirectly affects 
eating.
Gastrointestinal carbohydrate sensing
A variety of pathways have been implicated in the physi-
ological responses of the gut to carbohydrates. The most 
information concerns glucose transporters, which can 
be coupled to Na+ (e.g., SGLT1) or facilitative transport-
ers (e.g., GLUT1, GLUT2, GLUT5). SGLT1 on the apical 
surface of enteroendocrine cells [37, 38] contributes to 
glucose absorption via Na+-dependent active transport. 
The Na+ gradient is maintained by the sodium-potassium 
pump located on the basolateral membrane surface. 
Glucose uptake is therefore a secondary active-transport 
system in which ATPase indirectly provides the energy. 
SGLT1 mRNA is increased by high-carbohydrate meals 
[39]. SGLT upregulation was abolished in rats following 
chemical vagal deafferentation [40], suggesting a role of 
the vagus in carbohydrate uptake by enteroendocrine 
cells.
The release of GLP-1 from L-cells and glucose-
dependent insulinotropic peptide (GIP) from K cells is 
stimulated by the activation of SGLT1, as indicated by 
its blockade by the inhibitor of sodium-coupled uptake, 
phloridzin [41, 42]. Interestingly, GIP secretion requires 
nutrient absorption, whereas GLP-1 secretion is triggered 
just by presence of nutrients in the lumen.
SGLT1 mRNA is found at relatively high levels in 
K- and L-cells in both the small intestine and colon [43, 
44] and in the mouse colon [45]. SGLT3 has been impli-
cated in glucose-triggered serotonin (5HT) release from 
rat enterochromaffin cells and downstream activation of 
vagal afferents via 5HT-3 receptors [46, 47]. Thus, using 
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phosphorylated Ca/CAMKII (pCAMKII) as a marker of 
cells activated by elevated Ca2+, Vincent et al. [48] found 
that pCAMKII was detectable in rat enterochromaffin 
cells and in vagal-afferent cell bodies following luminal 
application of glucose, but not galactose. However, a full 
characterization of the substrate preferences of mouse 
SGLT3a and the rat SGLT3 isoforms is clearly required 
before it will be possible to use substrate and inhibitor 
pharmacology as reliable indicators of rodent SGLT3 
activation.
Dietary fructose stimulates GLP-1 secretion. Apical 
fructose transport in the intestine occurs via the facilita-
tive sugar transporter GLUT5, whose activity is not elec-
trogenic and has not been linked directly to activation 
of intracellular signaling pathways. Thus, the molecular 
identity of the GLUT5 sensor and how fructose triggers 
GLP-1 release in vivo remains obscure. L-cells express high 
levels of GLUT5 mRNA [44], suggesting they can take up 
fructose from the intestinal lumen. However, although 
absorbed fructose could enter the metabolic pathway, 
with consequent generation of ATP and closure of KATP 
channels, it seems unlikely that this accounts for fructose-
triggered GLP-1 release in vivo because the simple closure 
of KATP channels by sulphonylureas is not a sufficient 
trigger for secretion [49]. Perhaps the enhanced metabolic 
rate may generate additional signals, including ATP itself, 
that stimulate GLP-1 secretion.
The sweet-taste receptors α-gustducin and T1R2/
T1R3 also contribute to glucose sensing in enteroen-
docrine cells, particularly K- and L-cells. α-Gustducin 
knockout (KO) mice showed reduced levels of both GLP-1 
and GIP compared with wild-type mice [50]. However, 
expression profiling of purified K- and L-cells revealed 
no enrichment of mRNA for T1R2/T1R3 or α-gustducin in 
response to glucose [43, 44]. In humans, however, intra-
gastric infusion of the T1R2/T1R3 sweet-receptor inhibi-
tor lactisole reduced the GLP-1 response to glucose [51, 
52], indicating that T1R2/T1R3 sweet receptors mediate 
part of the direct effect of carbohydrates on GLP-1 secre-
tion. Clearly, further work is required to clarify the roles 
of sweet-taste receptor in gastrointestinal hormone 
secretion.
The last step of absorption, basolateral glucose 
efflux, is facilitated by GLUT2 in the proximal gastroin-
testinal tract and by GLUT1 more distally [45]. GLUT2 is 
transiently recruited to the apical-membrane surface after 
meals, allowing passive absorption of glucose at higher 
luminal glucose concentrations. Mace et al. [53] reported 
that sucralose doubled the rate of glucose absorption by 
increasing the expression of GLUT2. T1R2/T1R3 can act as 
a glucose sensor at high concentrations and may control 
the apical expression of GLUT2 and consequent increased 
capacity to absorb glucose.
Gastrointestinal lipid sensing
Ingested lipids are potent stimuli for the secretions of 
CCK, GIP, GLP-1, and PYY. Although enteroendocrine 
cells may sense triglycerides, most evidence indicates 
that prior lipolysis is required [54]. Long-chain fatty acids 
(LCFA; 12 carbons or more) are potent CCK secretagogues 
[55, 56]. The vagal stimulation that is required for these 
responses by LCFA has been attributed to an indirect 
process, whereby the free fatty acids (FFAs) are sensed by 
I cells and the release of CCK acts in a paracrine manner to 
stimulate CCK-1 receptors on the vagal afferents. For lipid-
induced CCK release, chylomicron formation is essential 
for this process. Pluronic L-81 or specific inhibitors of 
microsomal triglyceride-transfer protein inhibit chylomi-
cron formation and reduce CCK secretion [56]. Because 
enteroendocrine cells cannot produce chylomicrons, it 
is possible that neighboring enterocytes serve as lipid 
sensors. Chylomicron synthesis does not seem to play a 
role in fat-triggered GLP-1 and PYY release.
All FFA receptors (FFAR1–3, GPR120) are GPCRs 
[57–60], and enteroendocrine cells express their mRNA 
[43, 44, 61]. Medium-chain fatty acids and LCFAs activate 
FFAR1 (GPR40) and GPR120, which stimulate the Gq-
phosphatidylinositol pathway, increasing Ca2+ concentra-
tions and exocytosis [57, 59]. Knocking out FFAR1 in mice 
decreases high-fat diet-induced GLP-1 and GIP release [62] 
and impaired linoleic-acid-stimulated CCK secretion [63]. 
In vitro siRNA knockdown of GPR120 reduced both GLP-1 
and CCK secretion [59, 64].
FFAR2 (GPR43) and FFAR3 (GPR41) are present in the 
distal intestine, especially the colon. Small-chain fatty 
acids, which can activate GPR43 via either the Gq-phos-
phatidylinositol or the Gi/o pathways or GPR41 via the 
Gi/o pathway [60], are involved in colonic release of GLP-1.
GPR119 is in a special category because lipids do 
not activate it, but oleoylethanolamine (OEA) does [65]. 
GPR119 is present in L- and K-cells [43, 44] and participates 
in GLP-1, PYY, and GIP release [66]. Ingestion of nutrients 
stimulates the release of OEA in the small intestine, which 
can induce the release of GLP-1 [67].
Finally, CD36 is a transporter for FFAs that was ini-
tially described in taste papillae [68–71]. It is believed to 
act via Src-PTK-B, PLCb2, and TRPM5 and as a co-receptor 
for GPR120 [72]. CD36 is expressed in the brush border 
of duodenal and jejunal epithelia. CD36-KO mice have 
reduced OEA production and OEA-induced satiety [73], 
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the latter of which can be induced via PPARα activation 
[73, 74].
Gastrointestinal protein and amino acid sensing
The most information on protein sensing relates to CCK 
secretion. In vitro experiments using the STC-1 cell line 
indicate that CCK expression in response to peptones is 
mediated via GPR93 [75]. Although it has been shown that 
GPR93 recruits Gq-, Gs-, Gi-, and G12/13-mediated sign-
aling pathways [76–78], its role in physiological peptone 
sensing is still under investigation. L-Glutamate seems 
to act via the heterotrimeric T1R1/T1R3 receptor [79, 80], 
which is expressed in enteroendocrine cells [81]. L-Pheny-
lalanine couples with the CaSR receptor to activate a phos-
phatidylinositol pathway, which results in Ca2+-induced 
release of hormones including CCK [63, 82, 83].
In vitro studies using the GLUTag, NCI-H716, and 
STC-1 cell lines show that peptide transporters such as 
PepT1 (SLC15A1) and PepT2 (SLC15A2) are activated by 
protein hydrolysates, resulting in increased intracellular 
Ca2+ and hormone release. Glutamine stimulation, for 
example, leads to the release of GLP-1 from GLUTag and 
primary colonic cultures.
What neuroendocrine mechanisms mediate 
gastrointestinal satiation?
Vagus nerve
The importance of vagal afferents in satiation is reflected 
in the increase in meal size that follows selective surgi-
cal section of sensory abdominal vagal afferents. Con-
siderable effort has been devoted to determining the 
brainstem organization of gastrointestinal vagal affer-
ent projections. The NTS is the first synaptic site for 
gastrointestinal afferents of the IX and X cranial nerves 
(i.e., glossopharyngeal and vagus nerves, respectively). 
Reconstruction of these projections in the horizontal 
plane reveals a viscerotopic map, with the rostrocaudal 
distribution of terminal fields corresponding to their 
rostrocaudal origins in the gastrointestinal tract. Fur-
thermore, gastric and small-intestinal afferents project 
mainly to the commissural and medial nuclei of the NTS. 
In addition, several brain areas including the medial 
frontal cortex, insular cortex, central nucleus of the 
amygdala, paraventricular nucleus of the hypothalamus, 
lateral hypothalamic area, and others can influence the 
output of the NTS by virtue of their connectivity with the 
dorsal vagal complex and thus be involved in the control 
of normal digestive processes.
The dorsal motor nucleus of the vagus (DMX) is the 
major source of visceral efferents that make synaptic 
contact with postganglionic neurons located in the myen-
teric plexus of the intestinal wall. A viscerotopic organiza-
tional map also exists here, with the neurons innervating 
the small intestine being localized in the medial part of 
the nucleus.
Gastrointestinal peptides and satiation: introduction
Peptides secreted from the enteroendocrine cells of the 
small intestine signal negative-feedback information 
from meal-related food stimuli from the periphery to 
the brain. Although many gastrointestinal peptides are 
hypothesized to have satiation effects, for most of these, 
the physiological status of their satiation action is uncer-
tain. Natural physiological endocrine effects are assessed 
using six criteria: (a) the plasma levels of the molecule 
change during meals; (b) cognate receptors for the mol-
ecule are expressed at its site of action; (c) administra-
tion of the molecule to its site of action in amounts that 
reproduce prandial levels at that site are sufficient to 
cause satiation; (d) compounds eliciting the secretion of 
the molecule produce effects similar to its administration; 
(e) the inhibitory effects on eating occur in the absence 
of abnormal behavioral, physiological, or subjective side 
effects; and (f) premeal administration of selective ago-
nists and antagonists to the receptors for the molecule 
produce effects on eating consistent with their receptor 
pharmacologies; for example, an antagonist should delay 
eating if the molecule’s role is to initiate eating or cause 
an increase in meal size if the molecule is regarded as a 
meal termination signal. These six criteria are considered 
below for CCK, GLP-1, and PYY.
CCK
CCK is released from the duodenal and jejunal I-cells in 
response to nutrients. In 1973, Gibbs et  al. [84] reported 
that intraperitoneal injections of CCK-8 rapidly decreased 
food intake in rats. The effect seemed specific because 
CCK-8 did not decrease water intake or produce signs of 
malaise. The mode of action of CCK-8 on eating in rats was 
originally thought to be endocrine, a hypothesis based on 
other models of peptide action (e.g., pancreatic enzyme 
secretion). Moreover, in monkeys and humans [85], CCK 
plasma levels increase soon after meal onset. Subsequent 
research in rats disconfirmed this hypothesis because 
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(a) plasma CCK did not increase during meals in rats; 
(b) much more CCK-8 had to be infused intravenously to 
inhibit eating than to, for example, stimulate pancreatic 
exocrine secretion [86]; (c) intravenous infusion of a mon-
oclonal antibody to CCK abolished the pancreatic response 
to food, but it did not change eating, whereas a small-mol-
ecule CCK receptor antagonist did increase eating [87]; and 
(d) the inhibitory potency of CCK-8 was markedly reduced 
or abolished after infusion into the portal vein or into the 
systemic circulation [88–90]. Thus, it was concluded that 
CCK-8 inhibits food intake in rats through a paracrine 
mode of action. More recently, it has been shown that the 
endogenous form of CCK is CCK-58, and it and other larger 
forms of CCK were much more potent than CCK-8 when 
administered systemically, suggesting that CCK-58 may act 
in part via an endocrine mode of action in rats, as well.
Local infusion experiments indicate that CCK acts in 
the area of the pylorus and proximal duodenum to elicit 
satiation in rats [91]. Selective abdominal vagal deafferen-
tation further identifies the vagus as the route of the CCK 
satiation signal to the brain.
Intravenous CCK infusion was first reported to decrease 
eating in humans by Kissileff et al. in 1981 [92], but in view of 
the relatively high doses, however, it was uncertain whether 
the effects were physiological. Follow-up studies using 
clearly physiological infusion concentrations, however, indi-
cated that that CCK decreased eating in both lean and obese 
subjects without illness or other adverse effects [85, 93]. 
Another crucial criterion for physiological function, that 
antagonism reverses the satiating effect of the exogenous 
peptide, and when administered alone, stimulates eating, 
was soon fulfilled in both rats and humans [94, 95].
CCK’s satiating effects are mediated through inter-
actions with CCK-1 receptors [96–100]. The Otsuka Long-
Evans Tokushima fatty rat (OLETF) rat bears a spontaneous 
null mutation of the CCK-1 receptor gene and is hyper-
phagic and obese [101, 102]. Moran et al. [103] found that 
OLETF rats consumed larger meals and did not decrease 
eating after CCK injections. OLETF rats also showed a 
deficit in their eating responses to dietary fat in that they 
did not quickly compensate when switched to a high-
calorie/high-fat diet, leading to an exacerbation of their 
hyperphagia [104] nor did they reduce intake in response 
to intragastric loads of fat [104]. Covasa and Ritter [105] 
extended these findings by showing that OLETF rats have 
deficits in the satiation response to a variety of intestinal 
nutrient infusions, and when reductions in intakes were 
present, CCK-1 receptor antagonists did not affect them. 
However, work by Bi and Moran indicates that much of 
the eating phenotype of OLETF rats stems not from loss 
of intestinal CCK signaling but from loss of neuronal 
CCK signaling via CCK-1 receptors in the paraventricular 
nucleus of the hypothalamus.
Importantly, treatment with CCK-1 receptor antago-
nists decreased the satiating potency of ingested food 
but did not abolish it. Thus, CCK must interact with 
other mechanisms to control eating. Synergistic inter-
actions between CCK and several other negative-feed-
back signals have been identified, including orosensory 
nutrient stimuli [106], gastric volume [107], leptin [108], 
small-intestinal 5HT [109, 110], apolipoprotein AIV [111], 
pancreatic glucagon [112], amylin [113], and insulin [7].
CCK also changes the expression of a number of peptides 
and receptors in the abdominal vagal afferents, although 
these have not been shown yet to be part of CCK satiation. 
For example, CCK-8 increases the expression of cocaine 
and amphetamine receptor transporter (CART) [114] and 
decreases the expression of MCH [115] in the vagus. Finally, 
studies using c-Fos expression as an indicator of neuronal 
activity showed that in addition to the dorsal vagal complex, 
CCK-8 also activates neurons in the ventrolateral medulla, 
parabrachial nucleus, and forebrain nuclei including the 
central nucleus of the amygdala, paraventricular, dorsome-
dial, and arcuate nuclei of the hypothalamus. The roles of 
these presumably polysynaptic projections in the process-
ing and integration of the peripheral information produced 
by peripheral CCK through the stimulation of vagal afferent 
fibers is still under investigation.
GLP-1
Peripheral GLP-1 is secreted from enteroendocrine L-cells 
located mainly in the jejunum, ileum, and colon. However, 
duodenal food stimuli can elicit GLP-1 secretion via neuro-
humoral reflexes mechanisms, which most likely lead to 
the increases in GLP-1 plasma levels rise within minutes of 
the onset of meals. The vagus is an important component 
of these reflexes: (a) glucose- and fat-induced GLP-1 release 
was greatly reduced in rats by bilateral subdiaphragmatic 
vagotomy [116] and (b) postprandial GLP-1 secretion was 
blocked by pharmacological blockade of vagal signaling 
with muscarinic receptor (M1 and M2) or gastrin-releasing 
peptide antagonists [117]. Both M1 and M2 muscarinic 
receptor subtypes are expressed in L-cells and are thought 
to mediate neural regulation of GLP-1 secretion [117].
The GLP-1 receptor is a G-protein-coupled protein and is 
expressed widely throughout the periphery (enteric nervous 
system, vagal nerves, stomach, small and large intestine, 
adipose tissue, kidneys, etc.) and the brain. Whether GLP-1 
acts in the periphery, in the brain, or both to elicit satiation 
is not entirely clear. In the periphery, it probably acts at least 
in part in a paracrine manner in rats because intraperitoneal 
Asarian and Bächler: Neuroendocrine control of satiation      169
GLP-1 infusion decreased eating in a situation in which 
intraportal GLP-1 infusion did not [118]. Furthermore, once 
GLP-1 is released from the L-cells, it is rapidly degraded 
by the enzyme dipeptidyl peptidase IV (DPP-IV), which is 
expressed on capillary vessels throughout the body. If GLP-1 
survives the degradation by DPP-IV, it may reach the GLP-1 
receptors in the brain where it may act to elicit satiation.
Additional evidence that GLP-1 acts in the periphery 
to elicit satiation comes from antagonist studies showing 
that central administration of the potent and selective 
GLP-1 receptor antagonist exendin (9–39) did not block 
decreases in eating produced after peripheral administra-
tion of GLP-1 but did block decreases in eating after central 
injection of GLP-1. Moreover, exendin (9–39) administered 
in the periphery blocked the decreases in eating caused 
by endogenous GLP-1 secreted in response to intestinal 
nutrient infusions and peripheral GLP-1 administration. 
The enteric nervous system or the vagal afferents could be 
sites where peripheral GLP-1 can act. This is supported by 
evidence that subdiaphragmatic vagotomy abolishes the 
satiating action of intraperitoneal GLP-1 infusion, although 
not that of GLP-1 infusion into the hepatic portal vein.
GLP-1 is also synthesized by neurons of the NTS, which 
then project to forebrain structures including the hypo-
thalamus, hippocampus, and cortex, all of which express 
GLP-1 receptors. The relative contribution of central and 
peripheral GLP-1 to central GLP-1 receptor stimulation 
remains a matter of active research. For example, although 
GLP-1 administration in the lateral or fourth ventricle inhib-
its eating, the caudal brainstem, however, is sufficient for 
the inhibitory action of GLP-1 on eating because intra-
peritoneal or fourth ventricular injections of GLP-1 elicit 
satiation in decerebrate rats. Both peripheral and central 
injections of GLP-1 induce c-Fos expression in the PVN, and 
GLP-1 injections in the paraventricular nucleus, but not the 
arcuate, decrease eating, suggesting that peripheral and 
central injections of GLP-1 may decrease eating via differ-
ent neuronal mechanisms. Local peripheral infusions of 
exendin (9–39), such as done with CCK receptor antago-
nist, would be very helpful in resolving this issue.
High-fat diet decreases the eating-inhibitory effect 
of GLP-1 by diminishing its meal-related secretion or by 
reducing the number of L-cells in the small intestine. 
Obese subjects also show increases in DPP-IV activity.
GLP-1 decreases eating by reducing meal size, rather 
than meal frequency. Meal size was decreased when 5-min 
GLP-1 infusions were administered at the onset of the first 
meal size in spontaneous eating rats [119]. Chelikani et al. 
[120], however, showed that 3-h intrajugular infusions of 
GLP-1 decreased both meal size and meal frequency. This 
discrepancy in results may be due to the fact that Chelikani 
et al. used a less physiological approach by administering 
GLP-1 by constant infusions.
PYY
PYY is secreted mainly by the same L-cells that also secrete 
GLP-1. As with GLP-1, the secretion is biphasic, initially stim-
ulated by atropine-sensitive neural projections from the 
proximal small intestine, followed by direct nutrient stimu-
lation. Also, like GLP-1, it is secreted mainly in response to 
lipids and carbohydrates. PYY (1–36), the secreted form, is 
inactive until proteolyzed to PYY (3–36) by DPP-IV. In the 
periphery, the effects of PYY (3–36) on eating arise from its 
interactions with inhibitory GPCR Y2R receptors.
Batterham et al. [121] initially reported that intravenous 
infusion of PYY (3–36) reduced eating in humans. The design 
was unusual, however, in that infusions were done during 
the inter-meal interval and plasma PYY (3–36) levels had 
returned to basal levels before the test meal, thus limiting its 
use as a satiation test. It also remains unclear whether physi-
ological doses of PYY (3–36) are sufficient to acutely inhibit 
eating in rats or humans. Beglinger and colleagues [122, 123] 
found that only PYY (3–36) infusions that elicited plasma PYY 
(3–36) concentrations greater than those elicited by a large 
meals inhibited eating in humans. Furthermore, PYY (3–36) 
infusion often led to nausea, suggesting that the decreases 
in eating may simply represent a nonspecific aversive effect. 
In contrast, meal-contingent PYY (3–36) infusions reduced 
meal size in rats in the absence signs of aversion [124]. Fur-
thermore, Abbott et al. [125] reported that injection of a Y2R 
antagonist into the arcuate nucleus reduced the effect of 
intraperitoneal PYY (3–36) injection and when given alone 
increased eating, which both further supports the hypoth-
esis that endogenous PYY (3–36) is a normal physiological 
satiation signal and suggests the arcuate nucleus of the 
hypothalamus as its site of action. That may not, however, be 
the only site of action because the vagus also expresses Y2R, 
and vagotomy was reported to block the effect of intraperito-
neal injections of PYY (3–36) [126].
Brain metabolic sensing and 
satiation
Introduction
As described in the introduction and Figure 2, energy 
homeostasis is regulated by feedback from circulating 
energy metabolites and hormones involved in energy 
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metabolism and energy storage, which act on a widely 
distributed set of peripheral and central neurons, dubbed 
as “metabolic-sensing neurons”. Many of these signals, 
for example, blood glucose, reflect meal-related increases 
in absorption, energy metabolism (e.g., tissue glucose 
uptake, gluconeogenesis, etc.), and energy storage 
(blood glucose is usually increased in obesity). Others, 
for example, FFA and leptin, may reflect mainly energy 
storage. We focus on brain metabolic-sensing neurons, for 
which the most information is available.
Identification of metabolic sensors is a classic aspect 
of the study of homeostatic eating. Until recently, however, 
this research largely neglected how these mechanisms 
affect meals, relying instead on measures of total food 
eaten over days or longer periods. As a result, the evi-
dence that these feedback selectively control satiation 
was mainly indirect, based on the overwhelming evidence 
that the homeostatic control of eating is affected mainly 
by changes in meal size, summarized in the introduction. 
This disconnect between homeostatic control mechanisms 
and behavior is reflected in our review. Happily, however, 
recent work has begun to not only remedy this error but 
also reveal the neural mechanism through which metabolic 
nutrient sensing and gastrointestinal nutrient sensing con-
verge to generate an integrated satiation signal.
Which brain metabolic-sensing neurons  
contribute to satiation?
Introduction
Research beginning 60 years ago has identified and char-
acterized the activity of metabolic-sensing neurons in the 
hypothalamic arcuate, ventromedial nucleus, and lateral 
hypothalamic area. More recently, metabolic-sensing 
neurons also have been identified in the caudal brainstem 
[127]. According to the theory, when extracellular levels of 
the sensed metabolites or hormones reach a certain level, 
these neurons become either excited or inhibited and set 
in motion neural networks that control eating, energy 
expenditure, and metabolism. As our review reflects, 
however, demonstrations that metabolic-sensing neurons 
play a normal phasic or tonic physiological role in the 
control of meal size are still lacking.
Brain glucose sensing
Jean Mayer’s [128] classic glucostatic theory posited that 
brain glucose utilization controls eating. Since then, 
important milestones including identifying potassium 
as a key player in this process [128], electrophysiological 
recordings from ventromedial and lateral hypothalamic 
neurons that were glucose-excited (GE) or glucose-inhib-
ited (GI) [129–131], and further characterization of the K+-
channel involved in neuron’s response to glucose [132] 
provided a solid basis for experiments in the last two 
decades aimed at identifying how neurons sense glucose 
and their roles in health, obesity, and diabetes.
Ventromedial and arcuate nuclei glucose-sensing 
neurons alter their action potential frequency in response 
to changes in extracellular levels of glucose [133, 134]. 
GE neurons increase, whereas GI neurons decrease their 
action potential frequency in response to increases in 
extracellular glucose from 0.1 to 2.5  mM glucose [133]. 
Thus, their dynamic range spans the normal range of 
extracellular glucose levels in the brain, which are about 
∼10% of systemic blood glucose levels [135], and they are 
plausible normal physiological controls of eating. GE 
neurons require glucose metabolism for excitation [134, 
136, 137]; however, GI neurons comprise distinct popula-
tions, which either require glucose metabolism [136, 137] 
or sense the glucose molecule directly [138].
GE neurons sense glucose by a mechanism analo-
gous to that operating in pancreatic b-cells [134]. Glucose 
enters the cell via GLUT-2 transporters, is phosphorylated 
by glucokinase (GK), and is metabolized in the TCA cycle 
to increased intracellular levels of ATP. ATP inhibits ATP-
inhibited K+ channels (KATP channels), and the resultant 
Ca2+ influx depolarizes the cell [139]. The concentration-
response relationship for both KATP channel currents and 
action potential frequency of ventromedial nucleus GE 
neurons are steep, linear relationships for glucose concen-
trations between 0.1 and 1.5 mM. The slope then decreases 
sharply, and the concentration-response function pla-
teaus between 2.5 and 5 mM glucose [140], i.e., well above 
physiological levels. These data strongly suggest that the 
KATP channel on GE neurons plays an important role in 
physiological brain glucose sensing. Current data suggest 
that there may be multiple subtypes of GE neurons uti-
lizing alternate glucose-sensing strategies, for example, 
sensitive or not sensitive to the α-subunit of AMPK, an 
important cellular fuel gauge [141, 142].
The phenotype of arcuate nucleus GE neurons 
remains controversial. Some studies showed that the elec-
trical activity of proopiomelanocortin (POMC) neurons 
stimulated with glucose is consistent to that of GE neurons 
[141, 143] and correlated with changes in energy status 
[144]. Several observations, however, indicate that POMC 
neurons are not GE neurons: (1) GE neurons are not present 
in the region of the arcuate nucleus generally designated 
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as the location of POMC neurons [140]; (2) immunohis-
tochemical evaluation following electrophysiological 
recordings from GE neurons did not reveal POMC-positive 
neurons [140]; and (3) intracarotid glucose injections did 
not increase levels of c-Fos expression in POMC neurons 
[145].
GI neurons sense glucose differently than GE neurons. 
Although GLUT-2 and GK are also involved [136, 137, 146], 
the downstream cascade clearly involves AMPK [147], 
whose activation leads to NO production and CAMKK 
activation [148], leading to the depolarization of the GI 
neurons in response to decreased glucose [147].
The physiological relevance of GE and GI neurons 
is uncertain. Experiments performed in the early 1990s 
showed that a 5–10% decline in blood glucose levels 
occurred 12–15 min preceding spontaneous meals in rats 
and that blocking the decline with glucose infusions 
delayed meal initiation, providing a causal relationship 
of declines in glucose and the onset of the meal [149]. A 
problem with this evidence is that changes in blood glucose 
do not necessarily reflect changes in brain glucose. When 
Levin and colleagues [135] measured glucose in the blood 
and the ventromedial hypothalamus in spontaneously 
eating rats, they failed to find a clear relationship between 
ventromedial hypothalamus glucose changes and either 
the onset or termination of spontaneous meals or between 
blood glucose and ventromedial hypothalamus glucose 
before meals. These elegant experiments exemplify how 
high the bar is to unambiguously demonstrate a normal 
physiological role of neuronal signaling in eating, a point 
that should be kept in mind in the following discussion 
of other metabolic-sensing mechanisms and of the neural 
networks controlling eating.
Finally, it is also important to note that (a) the emer-
gency eating response to acute biochemical hypoglycemia 
involves ventromedial hypothalamus glucose sensing 
mediated by GK [135] and (b) it remains possible that 
glucose sensing in the portal vein or liver does contribute 
to the physiological control of meal size [150, 151].
Brain lipid sensing
Oomura et al. [152] suggested that FFA might have a facili-
tatory effect on glucose-sensitive neurons in the lateral 
hypothalamus. Wang et  al. [153] later showed that there 
are oleic acid-excited and oleic acid-inhibited neurons in 
the arcuate nucleus whose activity depended on the extra-
cellular glucose concentration. Le Foll et al. [154] showed 
that ∼40% of ventromedial hypothalamic neurons were 
excited and increasing concentrations of oleic acid 
inhibited 30%, but the activity of the ventromedial 
hypothalamic neurons was not dependent on ambient 
glucose concentrations. Furthermore, inhibition of acyl-
CoA synthetase, the initiating step in fatty acid metabo-
lism, manipulations of CPT1 activity, and reactive oxygen 
species formation, or blockade of KATP channel activity or 
the fatty acid transporter CD36 reduced activity of only 
20% of the excitatory and 40% of the inhibitory oleic acid-
sensitive neurons, suggesting that oleic acid levels rather 
than utilization affected ventromedial hypothalamus neu-
ronal activity through multiple pathways. FFA sensing by 
CD36, or fatty acid translocase/CD36, is especially inter-
esting because CD36 is a membrane FFA receptor/trans-
porter that does not require intracellular FFA metabolism 
to initiate signaling. In confirmation of the importance of 
such signaling, Moulle et al. [155] demonstrated that the 
eating-inhibitory effect of 10-min intracarotid, intralipid 
infusions was dependent on the expression of CD36 in 
the VMN and on acyl-CoA synthesis but not on fatty acid 
oxidation.
The initial tests of brain lipid sensing and eating 
involved intracerebroventricular injections of the fatty 
acid synthase inhibitors C75 and ceruleinin, which 
decreased eating and body weight in mice [156, 157]. The 
underlying lipid sensing mechanism is unclear. Some 
data suggest C75 reduces eating by decreasing pAMPK 
[158]. Obici et al. [159] extended these findings by showing 
that intracerebroventricular administration of oleic acid 
decreased eating, in part, by decreasing hypothalamic 
expression of neuropeptide Y (NPY) [159]. Obici and Ros-
setti [160] then suggested that fatty acid synthase inhibi-
tors and the intrahypothalamic oleic acid infusions lead 
to an accumulation of LCFA CoAs in the hypothalamus 
that, via a negative-feedback mechanism, signal lipid 
availability and inhibit eating. Indeed, inhibition of CPT-1 
in the arcuate nucleus increased levels of oleyl-CoA and 
was accompanied by low levels of agouti-related peptide 
(AgRP) and NPY mRNA levels. Interestingly, intrahypotha-
lamic oleic acid did not decrease eating or increase NPY 
mRNA expression in rats fed with high-fat diet [161].
The physiological relevance of brain lipid sensing has 
not been directly tested. Because plasma FFA levels do 
not rise during meals, they are unlikely to serve as phasic 
satiation signals related to ongoing meals. FFA levels do 
rise in obesity [162], suggesting a possible role as a tonic 
weight-regulatory satiation signal. If so, however, the 
brain must combine this information with other metabolic 
sensing because FFA levels also rise during fasting.
Another issue with brain lipid utilization sensing is 
that the brain fatty acid oxidation occurs in astrocytes, not 
neurons [163–165]. It is therefore possible that brain lipid 
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sensing is based on neuronal uptake of ketone bodies 
produced in astrocytes. Le Foll et  al. [24], using electro-
physiology and microdialysis techniques, confirmed this 
hypothesis by showing that (a) plasma and ventrome-
dial hypothalamic plasma b-hydroxybutyrate levels were 
higher in rats during the first hour of high-fat diet feeding 
following an overnight fast; (b) as ketones can have an 
overriding, excitatory action on either glucose or oleic 
acid stimulation of ventromedial hypothalamic neurons, 
the rats decreased eating; and (c) this eating-inhibitory 
effect was reversed by inhibition of ketone production by 
3-hydroxy-3-methylglutaryl-CoA synthase inhibitor.
Brain amino acid sensing
Initial studies by Cota et al. [166, 167] suggested an impor-
tant role for hypothalamic leucine sensing and down-
stream changes in mTOR and S6K1 in the control of eating 
and body weight as well as during diet-induced obese 
states. Work by Blouet and colleagues [127, 168, 169] has 
begun to unravel the eating effects of leucine sensing in 
ventromedial and arcuate nuclei of the hypothalamus and 
NTS in the control of eating. They demonstrated that in 
the fasted rats, (a) cerebrospinal fluid leucine concentra-
tions were 26 times lower than plasma leucine levels; (b) 
ingestion of a high-leucine meals raised the CSF leucine 
levels; (c) intraventricular infusions of leucine in the third 
or fourth ventricle decreased eating; (d) third ventricle 
injection of inhibitor of leucine metabolism (i.e., ketogen-
esis) decreased eating. These data strongly support the 
hypothesis that brain leucine sensing can physiologically 
control eating, at least under certain dietary conditions. 
An interesting point was that third ventricle leucine injec-
tions did not affect meal size after the first meal, but led 
to a large decrease in meal frequency, whereas fourth ven-
tricle leucine injections decreased meal size and not meal 
frequency. This suggests that NTS leucine sensing may 
be more important for the tonic contribution of satiation 
related to energy homeostasis than ventromedial/arcuate 
nuclei leucine sensing.
Brain insulin sensing
The hypothesis that insulin might provide a tonic signal 
linking adipose tissue energy stores to the control of 
eating arose from (a) Bagdade et  al.’s [170] reports that 
both basal, fasting insulin levels and glucose-stimu-
lated insulin levels are linearly correlated to adipose 
tissue mass, which they estimated by percent ideal body 
weight, and (b) a similar correlation between body weight 
and basal insulin in rats [171]. Insulin, as with leptin, has 
been demonstrated to regulate eating. Plasma insulin is 
low during fasting and increases mainly during and after 
meals. Both basal and prandial insulin levels are direct 
functions of the amount of white adipose tissue in the 
body [170, 172, 173]. Soon after, Woods and colleagues 
[174–176] reported that insulin infusions into the third 
ventricle or near or directly within the mediobasal hypo-
thalamus decreased eating and body weight in baboons 
and rats. The responses were dose-dependent [174, 
175] and apparently not related to illness [177]. Further 
important discoveries included the following: (a) insulin 
entered the brain; (b) brain insulin levels in the cerebro-
spinal fluid were higher in obese rats than lean rats; 
(c) insulin receptors exist in the brain; and (d) insulin 
receptors exist on NPY/AgRP and POMC neurons in the 
arcuate nucleus as well as other brain areas implicated 
in the control of eating (for a review, see [178]). Despite 
this wealth of data, however, the hypothesis that endo-
crine insulin functions, as a normal physiological endo-
crine adiposity signal, lacks crucial support: (a) whether 
physiological intravenous or central doses of insulin are 
sufficient to inhibit eating either acutely or tonically is 
not clear [179]; (b) although there are reports that acute 
central insulin antibody treatment increase eating [180], 
there are no demonstrations that chronic central insulin 
increases eating (there is a report that brain-specific 
transgenic deletion of insulin receptors increases eating 
and body weight in female mice, but this appeared not 
to be the case in males [181]; (c) basal levels of plasma 
insulin did not change in association with weight-regula-
tory eating responses in rats recovering from forced over-
weight [182] and in other situations [183].
Brain leptin sensing
Leptin is an adipokine hormone secreted by white adipose 
tissue. Leptin and leptin receptors were discovered in the 
search for the hormonal mechanism accounting for the 
hyperphagia/obesity phenotypes of the ob/ob (leptin-
deficient, now known as Lepob) or db/db (leptin recep-
tor-deficient, Leprdb) mice [184, 185]. Circulating leptin 
is taken up into the brain [186], and leptin receptors are 
highly expressed in NPY/AgRP and POMC neurons in the 
arcuate nucleus as well as in the dorsal vagal complex and 
other areas [187–189]. NTS neurons express leptin recep-
tors, and fourth ventricular and NTS injections of leptin 
inhibit eating, although whether this is a meal size effect 
has not been tested [190].
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Basal leptin levels are linearly correlated to fat mass. 
Although plasma leptin levels display a marked circadian 
variation, they are not affected by individual meals, so 
that their relation with fat mass is maintained consistently 
[191]. Evidence suggesting that leptin is a tonic satiation 
signal includes (a) three groups of investigators reported 
that doses of peripheral and central leptin that inhibited 
eating did so by reducing the size of the rats’ spontaneous 
meals without affecting the number of meals consumed 
[192] (fourth ventricular and NTS injections of leptin inhibit 
eating [190], but whether this is a meal size effect has not 
been tested); (b) chronic peripheral leptin treatment also 
reduced eating by selectively decreasing meal size [13, 14]; 
and (c) the hyperphagia due to genetic impairments of 
leptin signaling in rats and mice were characterized by 
meal size-specific alterations. Thus, the hyperphagia of 
ob/ob mice and Zucker rats (with deficits in leptin recep-
tors) are both characterized by chronic increases in the 
size of spontaneous meals [12, 193]. There is mixed support 
for the hypothesis that these effects reflect a normal 
physiological function: (a) physiological doses of leptin 
appeared sufficient to inhibit eating in mice [179]; (b) in 
obese humans tested after 10% weight loss, infusing leptin 
in amounts sufficient to reproduce pre-weight loss levels 
reversed subjective measures of meal-induced satiation 
[92]; (c) infusion of a leptin receptor antagonist over 1 week 
increased eating and weight gain [194]; (d) moreover, when 
infused together with leptin, the antagonist prevented the 
anorectic and weight-reducing responses to leptin as well 
as the increase in leptin signaling gain [194]. Because the 
antagonist neither stimulated leptin-induced STAT3 phos-
phorylation (see below) nor reduced the basal levels of 
phosphorylated STAT3, Zhang et al. concluded that in both 
tests, the agent actively antagonized the rat leptin receptor. 
Whether plasma leptin levels encode adiposity informa-
tion in all situations remains unclear, however, as several 
dissociations among adiposity, leptin levels, and weight-
regulatory eating have been reported [182, 183].
Leptin is a pleiotropic hormone that activates different 
intracellular signaling cascades in the brain. When it binds 
to the long signaling form of its receptor (Leprb), it recruits 
the Janus kinase (JAK). JAK binds to and phosphorylates 
Leprb [195], which activates STAT3. Once phosphorylated, 
STAT3 binds to pomc and agrp promoters, stimulating 
POMC and inhibiting AgRP expression [196,  197]. Leptin 
via Leprb also activates PI3K, which induces the synthe-
sis of PIP3 from PIP2 [144, 198, 199]. Accumulation of PIP3 
leads to PDK1 activation, which further activates protein 
kinase B (PKB, also know as AKT).
Interestingly, the leptin- and insulin-signaling path-
ways converge in PI3K activation [189, 200]. AKT, one of 
the PDK1 downstream targets, has an important role in the 
regulation and activation of many proteins and transcrip-
tion factors, such as FoxO1 [201, 202], AMPK [141], and 
mTOR [166]. FoxO1 acts as an inhibitor of POMC expres-
sion [203]. Leptin and insulin also regulate the AMPK 
signaling pathway in the hypothalamus [141]. Proteins 
involved in this pathway are hypothesized to sense energy 
status and are activated by energy deficiency [204]. Leptin 
and insulin inhibit the activation of AMPK and its down-
stream targets.
The mTOR pathway is also thought to be involved in the 
hypothalamic regulation of eating [166]. Intact mTOR sign-
aling is necessary for the eating-inhibitory effect of leptin 
[166]. In contrast to AMPK, hypothalamic mTOR expression 
is higher in situations of energy surplus, perhaps mediated 
by both leptin [166] and insulin signaling [205].
How does the brain integrate 
satiation feedback?
Introduction
The neurochemical and neurophysiological characteriza-
tion of the neural pathways underlying the effects of the 
hormone leptin on eating led to important insights into 
the neural networks controlling eating [206, 207]. In par-
ticular, both in the hypothalamus and in the DVC in the 
caudal brainstem, neurons that responded to leptin were 
also activated by other metabolic and gastrointestinal 
sensors. These findings established that the regulation 
of eating, energy expenditure, and adipose tissue metab-
olism is mediated by a distributed integratory neural 
network involving bidirectional communications between 
the forebrain and the hindbrain rather than by the hypo-
thalamus alone. In this section, we first review some of the 
key neurochemical signals involved in eating. An unfortu-
nate aspect of this work is that it often does not link the 
functions described to meal control. Therefore, we close 
by describing progress in understanding the convergence 
of forebrain neural networks on caudal brainstem control 
of networks mediating satiation.
Perhaps the most investigated neurons with respect to 
regulation of eating are the POMC and NPY/AgRP neurons 
in the arcuate nucleus. POMC neurons project throughout 
the brain, where they release α-melanocyte stimulating 
hormone (α-MSH), which binds to melanocortin recep-
tors 3 and 4 (MCR3 and MCR4). NPY/AgRP neurons release 
AgRP, an α-MSH inverse agonist that acts at the MCR to 
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counteract the effects of α-MSH. NPY exerts its effects on 
eating via NPY receptors (NPYR) (1, 2, 4, and 5), which are 
independent of MCR. The discovery of this ARC microcir-
cuit greatly accelerated the progress in understanding the 
neural control of eating, some of which we review below.
POMC neurons
Mouse models of Pomc and Mc3r/Mc4r deficiency display 
hyperphagia and obesity [208–210]. Central administra-
tion of melanocortin receptor agonists dose-dependently 
decreases short-term eating [211]. Both genetic and phar-
macological studies suggest that long-term activation of 
the melanocortin system may chronically decrease eating 
and body weight. Indeed, transgenic mice overexpress-
ing melanocortins show decreased eating and lower body 
weight gain and adiposity than controls [212, 213]. Long-
term effects on body weight have also been investigated 
using POMC-adeno-associated virus (POMC-AAV)-medi-
ated overexpression at specific sites within the brain. 
For example, hypothalamic POMC-AAV expression in the 
arcuate nucleus, but not at other hypothalamic sites, was 
sufficient to reduce the hyperphagia in leptin-deficient, 
obese rats [214]. POMC-AAV injections in the NTS and 
VTA also had the same inhibitory effect on eating and 
body weight gain in diet-induced obese rats [215, 216]. 
Aponte and colleagues [217] showed that optogenetic 
stimulation of POMC neurons in the arcuate nucleus 
was required for a long-term (24 h) rather than a short-
term (2 h) to decrease eating. Although this does not 
agree with previous findings about the latency of POMC 
neuronal activation to reduce eating, some alternative 
explanations should be considered: (a) POMC peptides 
diffuse slowly to their targets in the brain; (b) activation 
of POMC neurons decrease eating only under certain 
conditions (e.g., the onset of the dark cycle); (c) specific 
stimulation patterns may be required for POMC neurons 
to have effects on eating; and finally, (d) injections of a 
lentiviral gene delivery vector carrying a gene construct 
for production of α-MSH into the arcuate nucleus of the 
hypothalamus in mice led to a sustained attenuation of 
diet-induced obesity [218].
The NTS also contains a small but functionally 
important number of POMC neurons [219, 220]. To our 
knowledge, there is only pharmacological evidence that 
establishes the sufficiency of arcuate nucleus vs. NTS 
POMC neurons in the regulation of short-term eating. That 
is, Seeley et al. [221] demonstrated that injections of the 
nonselective MC4R antagonist SHU9119 into the third ven-
tricle of rats increased 4- and 24-h food intake. However, 
they did not test the effects of antagonist administration 
in conditions in which the third ventricle aqueduct was 
blocked, which would eliminate the possibility that the 
effect on eating was due to blockade of MC4R in the NTS. 
The necessity of arcuate nucleus POMC neurons in the 
regulation of short-term eating is still unclear.
In contrast to the case of the arcuate nucleus, more 
evidence supports a necessary role of the NTS POMC 
neurons in the regulation of eating behavior. Injections 
of the MC3/4R agonist MTII into the caudal brainstem are 
sufficient to decrease eating [222–224]. Furthermore, the 
effects on spontaneous eating following administration of 
MTII near the caudal brainstem or into the DVC are due to 
changes in meal size [225]. Using DREADD pharmacoge-
netic technology, POMC neurons were activated in either 
the arcuate nucleus or the NTS. Chronic, but not acute, 
activation of arcuate POMC neurons reduced eating, and 
their ablation resulted in hyperphagia and obesity. In 
contrast, acute stimulation of NTS POMC neurons rapidly 
reduced eating, and ablating this POMC neuronal popula-
tion did not produce any obvious changes in eating behav-
ior or body weight [226]. These results are consistent with 
the view that the POMC neurons in the arcuate nucleus 
are critical for maintaining long-term energy homeostasis 
and that the NTS POMC neurons contribute to short-term 
feeding control, i.e., probably in response to gastrointesti-
nal satiation signals.
An interesting aspect in the identification of the seg-
regation of roles between arcuate and NTS POMC neurons 
was revealed by a study performed by Zheng et al. [227], in 
which an adenoviral transfer vector expressing EGFP only 
when transduced into cre-expressing cells was used to 
exclusively label POMC neurons. They showed that unilat-
eral injection of this tracer resulted in GFP-positive axon 
profiles in the NTS and other areas of the caudal brain-
stem. To determine the proportion of NTS terminating 
α-MSH fibers that arises from arcuate-POMC neurons vs. 
NTS-POMC neurons, α-MSH immunoreactivity in the NTS 
and vicinity of intact rats were compared with those of 
decerebrate rats. In intact rats, very fine axon profiles and 
a moderate number of relatively large caliber axon profiles 
were present throughout the NTS. By contrast, in decer-
ebrate rats, most of the larger-caliber fibers were missing 
and only the fine immunoreactive fibers remained in this 
region. These results suggest that NTS neurons are sup-
plied with endogenous α-MSH both by arcuate- and NTS-
POMC neurons.
POMC neurons project to multiple brain sites, both 
intrahypothalamic and extrahypothalamic. The network 
of the POMC circuit can be divided into leptin-, insulin-, 
or 5HT-sensitive neurons [228, 229], and to a lesser extent, 
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leptin- and insulin-responsive neurons [230]. To release 
bioactive signaling molecules, POMC neurons integrate 
afferent signals until a depolarization induces the release 
of peptidergic vesicles and granules in a calcium-depend-
ent manner [231, 232]. According to classically described 
mechanisms, boutons in presynaptic terminals should 
release neuropeptides onto other neurons expressing the 
appropriate receptors. Interestingly, peptides released 
from POMC neurons can be detected at sites devoid of 
postsynaptic receptors and at nonsynaptic sites as well 
[233–236]. Accordingly, POMC neurons may participate 
both in synaptic and volume transmission in the brain 
[237, 238].
Given that POMC neuronal fibers are present around 
the ventricles through the entire rostrocaudal extent of 
the brain, an important aspect of these phenomena is 
that the neuropeptides released by POMC neurons can 
enter the cerebral ventricles and act at sites lacking direct 
POMC synaptic control [239–241]. This possibility was 
confirmed by findings that ICV administration MTII can 
reduce or increase eating, respectively [242–244]. MTII 
reduced intake of scheduled glucose meals and of over-
night spontaneous pellet intake [245]. These extended 
previous findings that MTII decreases eating during the 
dark phase [222, 223]. MTII selectively reduced meal size 
and meal duration, with no change in meal frequency 
[245], suggesting that MTII reduces eating by increasing 
the satiating potency of negative-feedback signals critical 
to satiation. Interestingly, however, MTII did not affect the 
reductions in eating produced by intraduodenal glucose 
infusions [245], suggesting that MTII does not modulate 
the potency of gastrointestinal satiation signals. Thus, 
more work is required to determine the functional signifi-
cance of α-MSH signaling.
Central melanocortins have been proposed as down-
stream mediators of the effects of leptin [246]. The first 
evidence for this was a report of Seeley et  al. [221] that 
administration of the MC4R antagonist SHU9119 into the 
third ventricle immediately before a leptin injection com-
pletely blocked leptin’s effect on eating. This appeared 
selective to leptin because SHU9119 did not block the 
effect of third ventricle administration of GLP-1 [221]. The 
interaction appears to occur within hypothalamic POMC 
neurons because they express leptin receptors [187] and 
leptin activates them, as shown both by increases in 
c-Fos expression [247] and by electrophysiological record-
ings [188]. Leptin administration in nondeprived rats 
increased POMC mRNA in the hypothalamus [248]. Mice 
selectively deficient for leptin receptors on POMC neurons 
were less obese than mice globally deficient in leptin 
receptors [249], and the difference developed as a result 
of decreased energy expenditure, rather than increases 
in eating behavior. Thus, MC4R signaling is selectively 
involved in leptin’s effect on eating.
There are several indications that caudal brainstem 
MC4R contribute to the mediation of eating by hindbrain-
delivered leptin. Caudal brainstem application of leptin 
decreased eating similarly to effects of fourth ventricu-
lar or NTS injections of MTII [190, 250, 251], and this was 
reversed by MC4R antagonist pretreatment [250]. These 
data suggest that caudal brainstems MC4R are part of the 
downstream mediation of hindbrain-induced effects on 
eating. POMC-EGFP mice were used to investigate whether 
the NTS POMC neurons are also leptin-signaling neurons. 
The advantage of this method is that the POMC neurons 
can be unambiguously identified in the NTS, whereas 
immunocytochemical or in situ hybridization methods 
failed before. Systemic leptin induced pSTAT3 immuno-
reactivity in NTS POMC-EGFP neurons that were located 
mostly caudal to the AP [252]. These results indicate that 
NTS POMC neurons are leptin-signaling neurons.
The eating-inhibitory effect of insulin may also involve 
POMC neurons. Injections of SHU9119 in the third ventricle 
attenuated the reduction in eating caused by insulin injec-
tions to the third ventricle [253, 254], and after a prolonged 
fast, POMC expression in the arcuate nucleus was attenu-
ated by insulin, consistent with previous findings that low 
levels of insulin in diabetic rats was accompanied by low 
levels of POMC expression, and it is restored by systemic 
insulin treatment [254]. Insulin receptors are expressed 
on POMC neurons in the arcuate nucleus [253], although 
whether they are also expressed by POMC neurons in 
the NTS or other regions of the hindbrain has not been 
investigated. In the arcuate nucleus, insulin hyperpolar-
izes POMC neurons [141, 189, 228, 255]. In contrast to the 
effect of leptin receptor lesions, the selective ablation of 
insulin receptors in POMC neurons had no effect on eating 
[189]. In another study, however, when insulin receptors 
were re-expressed in insulin receptor KO mice, food intake 
increased [256].
Numerous lines of evidence suggest that 5HT-2CR in 
POMC neurons constitute a key node governing eating: 
(a) POMC neurons in the ARC express 5HT-2CR and receive 
input from other 5HT-immunoreactive terminals [257, 258]; 
(b) 5HT-2CR agonists stimulated POMC neurons in the 
arcuate nucleus [259, 260]; and (c) 5HT-2CR reactivation 
specifically in the POMC neurons of otherwise 5HT-2CR-
null mice improved energy homeostasis [261, 262].
Serotonin’s effects on eating may involve several 
mechanisms: (a) direct activation of arcuate POMC 
neurons via 5HT-2CR; (b) indirect 5HT-1BR-mediated disin-
hibition of POMC neurons via blockade of local inhibitory 
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inputs; and (c) direct inhibition of AgRP neurons [229, 
257, 263]. Recent data demonstrate that 5HT-2CR signal-
ing in the POMC neurons is required to maintain energy 
homeostasis. Selective loss of 5HT-2CR signaling in POMC 
neurons resulted in hyperphagia and sensitization to diet-
induced obesity and blunted the effects of D-fenfluramine 
and mCPP to suppress eating [264]. These data support 
the role of POMC neurons in the arcuate nucleus in the 
control of eating, in contrast to the demonstration that 
leptin receptor signaling via POMC neurons did not affect 
eating, only energy expenditure [255, 265]. It is important 
to note that 5HT-2CR and leptin receptors are expressed by 
anatomically and functionally distinct POMC neurons in 
the arcuate nucleus, but these populations converge on 
similar second-order neurons, including those expressing 
MC4R [228, 229].
Finally, using an in vitro culture system of neurons 
expressing fluorophores under control of pomc 
transgenes that allowed electrophysiological charac-
terization of identified neurons, Hentges et al. [266, 267] 
showed that there are many GABAergic and few gluta-
matergic subpopulations of POMC neurons. Consistent 
with GABA release, approximately 40% of POMC neurons 
express GABA-synthesizing enzymes GAD65 and GAD67 
[266, 268]. Immunohistochemically, POMC axon terminals 
were readily identified as GABAergic or glutamatergic. To 
our knowledge, most of the evidence supporting a role of 
GABA receptors on POMC neurons on eating comes from 
one study in which mice that lacked metabotropic GABA 
receptors on POMC neurons were found to be heavier than 
WT mice, but only when the mice were placed on high-fat 
diet, and interestingly, it was more pronounced in male 
mice than in female mice [269].
AgRP/NPY neurons
The role of AgRP in the regulation of eating has been 
examined in a number of different rodent models. Some of 
the main findings are the following: (a) AgRP expression 
in the arcuate nucleus is increased during fasting and in 
mice with genetic leptin deficiency [248, 270, 271]; (b) both 
overexpression of AgRP and intracerebroventricular AgRP 
administration increased eating [272, 273]; (c) selective 
acute activation of AgRP neurons using DREADD pharma-
cogenetic technology [274] or optogenetic technology [217] 
induced voracious eating; (d) selective pharmacogenetic 
antagonism of AgRP neurons reduced eating [274]; (e) 
interestingly, however, reduction of hypothalamic AgRP 
expression by RNA interference decreased body weight 
independent of changes in eating [275].
As with POMC neurons, leptin and insulin modulate 
the activity of AgRP neurons. Deletion of leptin receptors 
on AgRP neurons increases body weight and adiposity 
[276]. When leptin receptors were deleted from both POMC 
and AgRP neurons, the mice became more obese, leading 
the authors to conclude that POMC and AgRP neurons 
work synergistically in response to leptin [276]. Insulin 
also acts on AgRP neurons in the arcuate nucleus [141, 
189]. Unlike leptin, however, selective ablation of insulin 
receptors on AgRP neurons had no effect on body weight 
or food intake [189]. Several groups devised strategies to 
ablate AgRP neurons to determine the importance of these 
neurons in eating and body weight regulation [277–280]. 
Consistent with the data reviewed above, the results indi-
cate that AgRP neurons are important for initiating meals 
and maintaining eating during meals in adult mice. Inter-
estingly, however, adaptive mechanisms can compensate 
for the germ line AgRP lesions.
Two hypotheses have been proposed to account for 
AgRP’s role in eating. First, AgRP exerts its action by 
blocking the binding of α-MSH to its receptor [271, 281–
283]. GABA release from AgRP neurons has a direct effect 
on POMC cells and probably on most postsynaptic MC4R-
bearing cells [188, 284, 285]. GABA co-localizes with NPY-
immuno-positive axon terminals that innervate local 
POMC neurons in both the arcuate and the paraventricu-
lar nuclei. Electrophysiological recordings indicate that 
leptin inhibits release of GABA from NPY terminals that 
synapse on POMC neurons [188]. Based on these observa-
tions, GABA output from AgRP neurons may be important 
in maintaining a dynamic balance with excitatory signal-
ing in certain postsynaptic target areas. Second, several 
lines of evidence suggest a melanocortin-independent 
pathway for AgRP. For example, AgRP still stimulated 
eating in MC4R-KO mice [30]. In addition, chronic block-
ade of the melanocortin pathway in A(y)/a genetic back-
ground (in which agouti protein is ectopically expressed 
in the brain, thereby chronically blocking MC4R signal-
ing) failed to ameliorate the severe anorexia after ablation 
of AgRP neurons [285].
The role of STAT3 in AgRP neurons has been examined 
in an attempt to identify the signaling mechanisms behind 
the role of AgRP neurons in the regulation of eating and 
body weight [196, 203, 286]. Data indicate that (a) STAT3 
activation by leptin inhibited AgRP mRNA expression 
levels; (b) STAT3 deletion led to mild in body-weight gain in 
mice, but unlike the deletions of STAT3 in POMC neurons, 
the effects were because of changes in energy expenditure; 
(c) overexpression of STAT3 in AgRP neurons increased 
locomotor activity, with no changes in eating [196]. As 
mentioned in Brain leptin sensing, the PI3K-PKD1-FoxO1 
Asarian and Bächler: Neuroendocrine control of satiation      177
signaling pathway acts to integrate leptin and insulin 
signals. PI3K is required for the actions of leptin and 
insulin on AgRP neurons [198, 287, 288]. Deletion of PDK1 
in AgRP neurons resulted in body weight loss as a conse-
quence of decreased eating and enhanced energy expendi-
ture [288]. Interestingly, in these same mice, leptin had an 
enhanced effect on eating. The specific deletion of FoxO1 
in AgRP neurons was associated with decreased eating, 
without a change in body weight [201].
Although NPY and AgRP are secreted from the same 
arcuate neurons, unlike AgRP, NPY is also expressed in 
many other brain areas [289]. When administered into 
the cerebroventricular system or directly into the hypo-
thalamus, exogenous NPY dose-dependently increases 
eating [290], and when it is administered chronically, 
body weight and body fat increase as well [290]. Whether 
injected into the hypothalamus [291–293] or the hindbrain 
[294–296], NPY elicits very-short-latency eating responses, 
typically seconds to minutes, and also prolongs eating 
once it has begun, with consequently larger meals being 
consumed. Thus, NPY both facilitates the onset of meals 
and delays satiation. Finally, the orexigenic response to 
NPY, similar with AgRP, is long lasting, often persisting for 
several hours or more [297–299].
There are data indicating that endogenous NPY also 
has an eating-stimulatory effect: (a) When antibodies to 
NPY were injected intraventricularly or directly into the 
VMH or PVN, food intake was decreased [300–302]; (b) 
administration of NPY antisense oligonucleotides or AAV 
to knock down endogenous NPY also inhibited eating 
[303, 304]. Further support for a role of endogenous NPY 
in eating comes from reports that fasting upregulated NPY 
mRNA in the ARC and NPY protein in the arcuate nucleus 
and paraventricular nucleus [305–308] and that these 
responses were reversed by refeeding [306, 309].
The dorsomedial hypothalamus is another site of 
NPY action. Bi [310] tested the effects of AAV-mediated 
NPY overexpression in the dorsomedial nucleus. Rats 
increased food intake by increasing nocturnal meal size 
and increased body weight, and being fed a high-fat diet 
augmented these effects. Bi also showed that in OLETF 
rats, which lack CCK-1 receptors and have elevated npy 
expression in the dorsomedial nucleus, NPY knockdown 
completely normalized nocturnal meal size [296].
The neural circuits underlying the actions of arcuate 
and dorsomedial hypothalamus NPY seem to differ. 
Arcuate NPY serves as a downstream mediator of leptin’s 
action on eating [311, 312], whereas dorsomedial NPY 
signaling is independent of leptin [313] but is affected by 
central (i.e., neurocrine, not endocrine) CCK signaling 
[314]. Hypothalamic NPY, however, may also be involved 
in mediating endocrine CCK satiation because NPY admin-
istration in the third ventricle reduced the ability of intra-
peritoneal CCK to inhibit eating. This behavioral response 
was supported by the fact that NPY reduced c-Fos expres-
sion elicited by peripheral CCK, whereas NPY alone did 
not elicit any c-Fos expression by itself [312, 315]. Because 
dorsomedial NPY neurons project to the NTS to modulate 
eating [296], these data suggest that both the dorsomedial 
hypothalamus and NTS are sites of action for the eating-
stimulatory effects of NPY.
Serotonin
Increasing (by administering a 5HT precursor) or decreas-
ing (by lesioning) 5HT function has profound effects on 
eating [316]. Blundell [317] was the first to propose that the 
serotonergic system is involved in satiation. Indeed, 5HT 
function is now associated with both within-meal satia-
tion and post-meal satiety [318]. Of the 14 subtypes of 5HT 
receptors now recognized, 5HT-2C and 5HT-1B receptors 
(2CR and 1BR, respectively) seem to mediate most of the 
effects of serotonergic drugs on eating behavior, appar-
ently via increased α-MSH release and reduced release 
[257, 263, 319].
Transgenic mice that lack 5HT-1BR exhibit increased 
body weight, which seemed to represent growth rather 
than obesity, and increased food intake that was in propor-
tion to weight [320]. In another study, however, 5HT-1BR-
KO mice displayed increased exploratory behavior but 
no change in food intake [321]. Serotonin 1BR agonists 
produce hypophagia, which is attenuated by 1BR antag-
onist treatment [322, 323]. Direct infusions of a 5HT-1BR 
agonist into the parabrachial nucleus of the pons, a 5HT 
target site, potently and selectively reduced eating [324]. 
The behavioral sequence of satiety was also preserved, 
with the onset of resting being advanced [322].
The role of serotonin in the control of appetite was 
initially examined with the serotonin releaser and reup-
take inhibitor fenfluramine and its selective enantiomer 
D-fenfluramine. Both drugs produced changes in eating 
behavior that were consistent with satiation, rather than 
hyperactivity and malaise [325–327]. The use of antagonists 
revealed that the effects of d-fenfluramine were mediated 
in part by 2CR receptors [328–330]. Selective serotonin 2CR 
agonists also increased satiation [331, 332]. Finally, mice 
lacking functional serotonin 2CR displayed marked hyper-
phagia, leading to the development of obesity [333,  334] 
and a normal behavioral sequence of satiety [329].
Pharmacological evidence indicates that peripheral 
CCK elicits satiation via brain serotonergic pathways 
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involving serotonin 2CR [335–337]. The pharmacological 
tools used, however, were not highly selective to 2CR and 
were not administered locally, which is important because 
several populations of serotonin receptors in the brain 
and in the periphery have been implicated in CCK satia-
tion. Studies in mice deficient in 2CR, however, showed 
that these serotonin receptors are crucial in the mediation 
of CCK satiation [338]. Furthermore, intraperitoneal injec-
tions of doses of GLP-1 that reduced eating in wild-type 
mice by 50–60% had no reliable effect in 2CR-KO mice 
[338]. These are the first data that we know implicating 
serotonin in GLP-1 satiation.
Several neuropeptides and neurotransmitters are 
involved in serotonin’s effect on eating. mCPP, a 2CR/1BR 
agonist, activated POMC- and inhibited AgRP-expressing 
neurons in the ARC [257, 260]. The downstream modula-
tion of the melanocortin system appears to be essential to 
the serotoninergic regulation of eating because A(y)/a mice, 
mice treated with SHU9119, and Mc4r-KO mice were all 
insensitive to d-fenfluramine and other serotonin recep-
tor agonists that induced hypophagia [260, 263]. Selective 
expression of 2CR only on POMC neurons is sufficient to 
normalize the hyperphagia and obesity and to attenuate 
responses to anorectic serotonergic drugs in 5HT-2CR-KO 
mice [261]. These data indicate that serotonin acting at the 
2CR expressed on POMC neurons mediate much of seroto-
nin’s effects on eating and body weight.
NPY neurons receive serotonergic inputs [263, 339] 
and are hyperpolarized by 1BR agonists [263]. Levels of 
NPY mRNA and protein were decreased by pharmaco-
logical serotonin increase [340, 341]. Moreover, feeding 
induced by NPY administration was attenuated by D-fen-
fluramine [342, 343]. The inhibition of NPY/AgRP neurons 
by 1BR action, coupled with the activation of opposing 
POMC neurons by 2CR action, suggests that these recep-
tors complement each other’s effects on at least one con-
vergent downstream pathway.
Oxytocin
In 1989, Arletti et al. [344] first demonstrated that intrac-
erebroventricular oxytocin reduced eating and intracer-
ebroventricular administration of an oxytocin receptor 
antagonist increased eating in rats. Since then, many 
studies have linked changes in brain oxytocin signal-
ing with changes in eating behavior: (1) hypothalamic 
oxytocin mRNA expression is reduced with fasting and 
is restored upon refeeding; (2) eating activated oxytocin 
neurons in rats; and (3) reduction of oxytocin mRNA and 
protein in the paraventricular nucleus led mice to develop 
obesity, which can be rescued by oxytocin treatment [345, 
346].
The mechanisms underlying the effects of oxytocin on 
eating are not well understood. Studies in rodents indi-
cate that oxytocin decreases eating primarily by decreas-
ing meal size and that hindbrain signaling is involved. 
Administration of an oxytocin antagonist alone stimulates 
eating [169, 344, 347–349] by increasing meal size [350]. 
Functional and anatomical data provide evidence that 
an interaction between oxytocin and hindbrain signaling 
mediates meal size.
Mice lacking oxytocin or oxytocin receptors develop 
late-onset obesity with little changes in daily food intake 
[351–353], and pair-feeding studies confirm that reduc-
tions in eating only partially account for oxytocin’s effect 
on body weight, suggesting that oxytocin also controls 
energy expenditure [354, 355].
Noradrenergic neurons
Neurons in the caudal brainstem noradrenergic A2 cell 
group are reciprocally connected with several brain 
regions. Direct projections from the cortex, limbic fore-
brain, and hypothalamus to the A2 cell group modulate 
a variety of visceral responses [356]. In turn, ascending 
projections from the A2 neurons provide a route through 
which feedback from the viscera affects not only hypotha-
lamic function but also emotional and cognitive process-
ing [356, 357].
Different subpopulations of A2 neurons are recruited 
by signals that increase or decrease eating, perhaps 
because different subpopulations target different brain 
regions and/or because different combinations of adren-
ergic receptors are expressed in those regions [358]. A2 
neurons seem to be activated in every experimental situ-
ation in which food intake is inhibited, including normal 
satiety [359–364]. A2 neurons are recruited in a graded 
manner in rats after eating, such that larger meals activate 
larger numbers of A2 neurons [365]. A2 neurons are also 
necessary for the satiating effect of CCK [351, 366, 367].
Forebrain-hindbrain neural networks for 
satiation
Satiation in the decerebrate rat
The general plan of a neural system for the control of the 
basic, rhythmic movements of eating consists of two cate-
gories of neurons: first, a network of neurons that generate 
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the rhythmic motor output, referred to as a central pattern 
generator (CPG), and second, all of the inputs to the CPG 
that turn it on and off. The CPG for licking, masticating, 
swallowing, and other eating movements are in the hind-
brain. These are normally controlled by local afferent 
stimuli that project to the hindbrain from the mouth, gas-
trointestinal tract, etc., and by descending inputs from the 
forebrain stimuli carrying information about the current 
environment, metabolic state, the effects of prior ingestive 
experience, mood, ongoing brain activities not directly 
related to eating, etc. Disconnecting the caudal brain-
stem from the forebrain thus should reveal the capacity of 
afferent stimuli that project to the caudal brainstem below 
the level of the disconnection to control the CPG in the 
absence of forebrain afferent stimuli. Grill and Norgren 
[368] have accomplished this analysis by investigating the 
control of liquid intake in the chronic decerebrate rat.
The decerebrate rat, even when food deprived, does 
not initiate eating despite the presence of food in its envi-
ronment. If liquid food is infused into the mouth through 
a chronically implanted oral catheter, however, the decer-
ebrate rat initiates eating. It continues for a time and then 
stops, allowing the infused liquid to drain out of its mouth; 
importantly, it does not emit mouth movements indicative 
of aversion, such as when bitter food is infused. Further-
more, after eating, it grooms and then is quiescent. Thus, 
like an intact rat, the decerebrate rat eats meals. In addition, 
the size of these meals is sensitive to feedback control; for 
example, decerebrate rats eat more of sweeter food and eat 
less after CCK injection. With regard to metabolic sensing, 
the picture is more complicated – decerebrate rats eat more 
in response to 2-deoxy-d-glucose, which blocks glucose 
metabolism but not in response to mercaptoacetate, which 
blocks fatty acid oxidation. They also fail to respond to 
food deprivation [369]. These results demonstrate that (a) 
the disconnected caudal brainstem has sufficient capac-
ity to integrate a variety of positive and negative feedback 
and to appropriately control the CPG for eating so as to 
produce a near-normal meal and (b) a variety of controls 
of eating and satiation depend critically on the forebrain. 
The next sections consider, first, some evidence concern-
ing neural basis of the integrative capacity of the caudal 
brainstem and, second, how forebrain controls reach the 
caudal brainstem, research that represent the beginning of 
the construction of a complete neural network for satiation.
Caudal brainstem integrative networks
DVC POMC neurons are involved in the control of eating by 
CCK. In a series of experiments, Fan and colleagues [370] 
showed that CCK activates NTS POMC-EGFP neurons and 
that CCK treatment fails to elicit satiation in MC4R-KO 
mice. Berthoud [371] found that hyperphagia induced by 
the MC4R antagonist SHU-9119 injected into the fourth 
ventricle was characterized by increases in meal size, 
with no effect on meal frequency (see also [372]). The 
same results were reported following fourth ventricular 
injections of MTII. A suggested mechanism for the inter-
action of the melanocortin and CCK signaling systems 
comes from studies revealing that MC4R are expressed 
presynaptically on vagal afferents and postsynaptically 
on NTS neurons themselves [373]. Because the neurons 
stimulated with MTII responded with an increase in EPSP 
frequency, the authors concluded that MC4R signaling 
involves presynaptic enhancement of glutamate synap-
tic transmission and suggested that it is this mechanism, 
rather than postsynaptic activation of NTS neurons, 
that may account for the melanocortinergically induced 
decreases in eating via enhancement of vagal afferent 
satiation signals from the gastrointestinal tract.
Brainstem leptin signaling seems act by modulating 
CCK satiation. This is because Hayes et  al. [374], using 
an RNA interference method, found that selective knock-
down of Leprb in the NTS increased food intake and body 
weight and decreased CCK satiation. There is also a very 
similar interaction between leptin and GLP-1 satiation 
signaling in the NTS [375].
Finally, injections of d-fenfluramine and serotonin 
receptor agonists to the fourth ventricle reduced eating in 
decerebrate rats, suggesting that serotonin action in the 
caudal brainstem is sufficient to provide some level of 
control over food intake [376, 377].
Descending projections for satiation
Several lines of research indicate that forebrain eating-
control signals do not project directly to caudal brainstem 
CPG but rather to circuits that integrate gastrointestinal 
satiation mechanisms. Perhaps the first evidence for this 
were reports that insulin and leptin increased the sati-
ating potency of peripheral CCK in a dose-dependent 
manner [378]. These latter investigators then localized 
the leptin/CCK interaction at least in part to the NTS by 
demonstrating that leptin also increased the potencies 
of both CCK [379] and intragastric nutrient loads [379] 
to activate neurons in the NTS, as indicated by c-Fos 
immunochemistry.
Morton et  al. [380] elegantly extended these earlier 
findings using Koletsky rats, which bear a global Leprb 
defect. They demonstrated that (a) these rats have 
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increased meal size, a decreased satiation response to 
exogenous CCK, and reduced c-Fos expression in the 
NTS after CCK injection and (b) transgenic replacement 
of Leprb specifically in the arcuate nucleus normalized 
all three defects. The same investigators [372] went on to 
identify the forebrain-brainstem projection that is likely 
to be involved in this interaction by showing that (a) the 
injection of an MC4R antagonist into the paraventricular 
nucleus reduced CCK satiation and (b) PVN neurons that 
were labeled after injection of a retrograde neuronal tracer 
into the NTS and collected by laser-capture microdissec-
tion express MC4R.
Oxytocinergic projections from the hypothalamus to 
the caudal brainstem are also involved in the control of 
eating. Oxytocin projections comprise ∼6% of all para-
ventricular nucleus projections to the DVC and provide its 
sole source of oxytocin [361, 381, 382]. Release of oxytocin 
from descending paraventricular nucleus-NTS projec-
tions enhanced visceral afferent transmission to the NTS 
[383]. Kirchgessner and her colleagues [384] provided the 
initial suggestion that this projection is involved in eating 
by showing that knife cuts that sever the paraventricular 
nucleus-hindbrain oxytocin projections resulted in hyper-
phagia and obesity. More recently, Blevins and colleagues 
[385, 386] confirmed this and also showed that reduc-
tions in hindbrain oxytocin signaling reduce the satiat-
ing potency of CCK in rats. Leptin also seems to affect this 
oxytocin signaling: (1) leptin activated paraventricular 
nucleus oxytocin neurons and increased the expression of 
oxytocin mRNA in the paraventricular nucleus, probably 
via melanocortin-dependent mechanisms [345, 350, 387, 
388] and (2) third ventricular administration of oxytocin 
antagonists blunted leptin’s anorectic effects and abol-
ished its ability to enhance CCK activation of the NTS [350] 
as well as reversing the anorectic effect of α-MSH [389].
Conclusions
We have reviewed the basic physiology of satiation. Eating 
contributes to the regulation of energy homeostasis via 
control of satiation. Gastrointestinal nutrient sensing gen-
erates negative-feedback signals encoded as concentra-
tions of the peptides CCK, GLP-1, and PYY (3–36) secreted 
during meals. There is substantial evidence that each of 
these contributes to the normal physiological control of 
satiation. Metabolic-sensing neurons located mainly in 
the hypothalamus and caudal brainstem react to circulat-
ing levels of glucose, FFA, leucine, leptin, and insulin to 
generate signals that may also contribute to satiation, but 
the physiological status of most of these is not yet firmly 
established. A number of neurotransmitters are involved 
in the processing of these signals into satiation. A main 
feature of this processing is that information derived from 
metabolic-sensing neurons converges on the caudal brain-
stem interneuronal networks that process information 
derived from gastrointestinal nutrient-sensing rather than 
projecting directly onto the motor neural networks that 
finally control eating. Progress in understanding these 
control of satiation should provide a platform for future 
research addressing the physiologies of the myriad other 
controls of satiation such as food reward, cognitive, and 
social controls. Furthermore, better understanding of the 
operation of this satiation system described here should 
suggest opportunities for novel peripheral and brain 
manipulations that may improve therapies for overeating 
and obesity and the many diseases that they lead to.
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